Ac Immune Stock Performance
| ACIU Stock | USD 2.19 0.05 2.23% |
The firm owns a Beta (Systematic Risk) of 0.64, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AC Immune's returns are expected to increase less than the market. However, during the bear market, the loss of holding AC Immune is expected to be smaller as well. At this point, AC Immune has a negative expected return of -0.31%. Please make sure to confirm AC Immune's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if AC Immune performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days AC Immune has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 1.36 | Five Day Return (4.68) | Year To Date Return (21.40) | Ten Year Return (85.70) | All Time Return (85.70) |
1 | AC Immune SAs last weeks 11 percent decline must have disappointed retail investors who have a significant stake | 12/19/2024 |
2 | Johnson Johnsons Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimers Disease | 01/08/2025 |
3 | 3 US Penny Stocks With Market Caps Over 100M To Consider | 02/03/2025 |
4 | Down -9.7 percent in 4 Weeks, Heres Why You Should You Buy the Dip in AC Immune | 02/13/2025 |
5 | AC Immune to Participate in Upcoming Investor Conferences | 03/04/2025 |
6 | AC Immune surges on Phase II data for Roche-partnered anti-tau antibody - FirstWord Pharma | 03/07/2025 |
| Begin Period Cash Flow | 78.5 M |
ACIU |
AC Immune Relative Risk vs. Return Landscape
If you would invest 270.00 in AC Immune on December 19, 2024 and sell it today you would lose (51.00) from holding AC Immune or give up 18.89% of portfolio value over 90 days. AC Immune is currently does not generate positive expected returns and assumes 2.8661% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than ACIU, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AC Immune Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AC Immune's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AC Immune, and traders can use it to determine the average amount a AC Immune's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1076
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACIU |
Estimated Market Risk
| 2.87 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AC Immune is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AC Immune by adding AC Immune to a well-diversified portfolio.
AC Immune Fundamentals Growth
ACIU Stock prices reflect investors' perceptions of the future prospects and financial health of AC Immune, and AC Immune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ACIU Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (16.37) % | ||||
| Current Valuation | 41.99 M | ||||
| Shares Outstanding | 100.41 M | ||||
| Price To Earning | (16.96) X | ||||
| Price To Book | 1.76 X | ||||
| Price To Sales | 8.13 X | ||||
| Revenue | 27.31 M | ||||
| Gross Profit | (35.26 M) | ||||
| EBITDA | (48.62 M) | ||||
| Net Income | (50.92 M) | ||||
| Cash And Equivalents | 154.15 M | ||||
| Cash Per Share | 1.83 X | ||||
| Total Debt | 5.43 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 13.28 X | ||||
| Book Value Per Share | 1.12 X | ||||
| Cash Flow From Operations | 65.84 M | ||||
| Earnings Per Share | (0.58) X | ||||
| Market Capitalization | 221.91 M | ||||
| Total Asset | 230.91 M | ||||
| Retained Earnings | (368.24 M) | ||||
| Working Capital | 71.16 M | ||||
| Current Asset | 160 M | ||||
| Current Liabilities | 11 M | ||||
About AC Immune Performance
Assessing AC Immune's fundamental ratios provides investors with valuable insights into AC Immune's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the AC Immune is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.30) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | (0.45) | (0.48) |
Things to note about AC Immune performance evaluation
Checking the ongoing alerts about AC Immune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AC Immune help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AC Immune generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 27.31 M. Net Loss for the year was (50.92 M) with loss before overhead, payroll, taxes, and interest of (35.26 M). | |
| AC Immune has a poor financial position based on the latest SEC disclosures | |
| About 38.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: AC Immune surges on Phase II data for Roche-partnered anti-tau antibody - FirstWord Pharma |
- Analyzing AC Immune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AC Immune's stock is overvalued or undervalued compared to its peers.
- Examining AC Immune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AC Immune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AC Immune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AC Immune's stock. These opinions can provide insight into AC Immune's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.